Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism

American Journal of Pathology

Volumn 178, Issue 5, 2011, Pages 2205-2214

  Advani, Andrew ^a   Huang, Qingling ^a   Thai, Kerri ^a   Advani, Suzanne L ^a   White, Kathryn E ^b   Kelly, Darren J ^c   Yuen, Darren A ^a   Connelly, Kim A ^a   Marsden, Philip A ^a   Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; KIDNEY INJURY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

EID: 79959209876     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.01.044     Document Type: Article

References (47)

1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653 (Pubitemid 41817713)
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589
3. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM, Dimmeler S: Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002, 91:837-844 (Pubitemid 35285082)
4. Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, Natarajan M, Abboud-Werner SL: Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 2008, 88:515-528 (Pubitemid 351581457)
5. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC: Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006, 17:2664-2669 (Pubitemid 44484656)
6. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007, 18:539-550 (Pubitemid 46193319)
7. Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, Takahashi T: Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 2007, 170:1473-1484 (Pubitemid 47339294)
8. Xia Y, Tsai AL, Berka V, Zweier JL: Superoxide generation from endothelial nitric-oxide synthase: a Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998, 273:25804-25808
9. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr: Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998, 95:9220-9225 (Pubitemid 28506212)
10. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820
11. Advani A, Gilbert RE, Thai K, Gow RM, Langham RG, Cox AJ, Connelly KA, Zhang Y, Herzenberg AM, Christensen PK, Pollock CA, Qi W, Tan SM, Parving HH, Kelly DJ: Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol 2009, 20:730-741
12. Santilli F, Cipollone F, Mezzetti A, Chiarelli F: The role of nitric oxide in the development of diabetic angiopathy. Horm Metab Res 2004, 36:319-335 (Pubitemid 38703794)
13. Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714
14. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T: Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009, 20:2503-2512
15. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 2002, 99:2995-3000 (Pubitemid 34240574)
16. Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006, 12:5199-5206 (Pubitemid 44453349)
17. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE: Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 2007, 104:14448-14453 (Pubitemid 350003281)
18. Advani A, Kelly DJ, Cox AJ, White KE, Advani SL, Thai K, Connelly KA, Yuen D, Trogadis J, Herzenberg AM, Kuliszewski MA, Leong-Poi H, Gilbert RE: The (pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 2009, 54:261-269
19. Hirose K, Osterby R, Nozawa M, Gundersen HJ: Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 1982, 21:689-695 (Pubitemid 12124298)
20. Osterby R, Gundersen HJ, Nyberg G, Aurell M: Advanced diabetic glomerulopathy: quantitative structural characterization of nonoccluded glomeruli. Diabetes 1987, 36:612-619 (Pubitemid 18024737)
21. Fish JE, Yan MS, Matouk CC, St Bernard R, Ho JJ, Gavryushova A, Srivastava D, Marsden PA: Hypoxic repression of endothelial nitricoxide synthase transcription is coupled with eviction of promoter histones. J Biol Chem 2010, 285:810-826
22. Haorah J, Knipe B, Leibhart J, Ghorpade A, Persidsky Y: Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction. J Leukoc Biol 2005, 78:1223-1232 (Pubitemid 41779228)
23. Siddens LK, Henderson MC, Vandyke JE, Williams DE, Krueger SK: Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms. Biochem Pharmacol 2008, 75:570-579 (Pubitemid 350298474)
24. Ahn K, Huh JW, Park SJ, Kim DS, Ha HS, Kim YJ, Lee JR, Chang KT, Kim HS: Selection of internal reference genes for SYBR green qRT-PCR studies of rhesus monkey (Macaca mulatta) tissues. BMC Mol Biol 2008, 9:78
25. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26:1351-1356
26. Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnol 2007, 25:84-90 (Pubitemid 46087907)
27. Bush EW, McKinsey TA: Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 2010, 106:272-284
28. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS: Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003, 111:539-552 (Pubitemid 36228011)
29. Marumo T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T: Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 2010, 298:F133-F141
30. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S: Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2009, 297:F996-F1005
31. Yoshikawa M, Hishikawa K, Marumo T, Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 2007, 18:58-65 (Pubitemid 46053422)
32. Tischler JL, Abuaita B, Cuthpert SC, Fage C, Murphy K, Saxe A, Furr EB, Hedrick J, Meyers J, Snare D, Zand AR: Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors. J Enzyme Inhib Med Chem 2008, 23:549-555
33. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K: Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005, 16:27-45 (Pubitemid 43073154)
34. Yagame M, Kim Y, Zhu D, Suzuki D, Eguchi K, Nomoto Y, Sakai H, Groppoli T, Steffes MW, Mauer SM: Differential distribution of type IV collagen chains in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus. Nephron 1995, 70:42-48
35. Dai Y, Rahmani M, Dent P, Grant S: Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage: XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005, 25:5429-5444 (Pubitemid 40853579)
36. Portanova P, Russo T, Pellerito O, Calvaruso G, Giuliano M, Vento R, Tesoriere G: The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int J Oncol 2008, 33:325-331
37. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784 (Pubitemid 44348499)
38. Shein NA, Grigoriadis N, Alexandrovich AG, Simeonidou C, Lourbopoulos A, Polyzoidou E, Trembovler V, Mascagni P, Dinarello CA, Shohami E: Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J 2009, 23:4266-4275
39. Leng Y, Chuang DM: Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006, 26:7502-7512 (Pubitemid 44315219)
40. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, Ratan RR, Langley B: HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci U S A 2009, 106:19599-19604
41. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB: Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 2009, 297:F729-F739
42. Fish JE, Matouk CC, Rachlis A, Lin S, Tai SC, D'Abreo C, Marsden PA: The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code. J Biol Chem 2005, 280:24824-24838 (Pubitemid 40934573)
43. Robb GB, Carson AR, Tai SC, Fish JE, Singh S, Yamada T, Scherer SW, Nakabayashi K, Marsden PA: Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript. J Biol Chem 2004, 279:37982-37996. (Pubitemid 39195514)
44. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840
45. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM: Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Physiol 1993, 265:F886-F895
46. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H: Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998, 41:1426-1434 (Pubitemid 28551613)
47. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD: Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005, 54:2628-2637 (Pubitemid 41233584)